Johnson & Johnson Received FDA Clearance for Ottava System
The company’s table-integrated surgical robot was authorized for 10 general surgery procedures in July 2026.
Updated on Sept. 28, 2026 in Robotics
Live Poll
Do you believe new robotic surgical technology improves care and hospital efficiency in your community?
In July 2026, the FDA granted De Novo authorization for the Ottava surgical robotic system, a new platform designed by Johnson & Johnson. The system integrates robotic arms directly into the surgical table to provide surgeons with greater flexibility in the operating room.
Why it matters
The system design aims to address common spatial constraints in surgical suites by consolidating robotic infrastructure. By moving away from traditional boom- or cart-mounted designs, Johnson & Johnson is attempting to streamline the surgical workflow for general procedures.
The Ottava system features robotic arms with nine motorized joints and up to 540 degrees of articulation, representing a 30% to 50% footprint reduction compared to competing boom- and cart-mounted systems. The surgeon console utilizes hand controls with seven degrees of freedom.
The players
Johnson & Johnson
A global healthcare conglomerate that produces medical devices, pharmaceuticals, and consumer products, with an expanding footprint in digital surgery.
Intuitive Surgical
The market leader in robotic-assisted surgery, best known for its da Vinci surgical systems which utilize a cart-based architecture.
The details
The Ottava platform differentiates itself by integrating four robotic arms into the surgical table itself, rather than requiring separate floor-standing units. Through Twin Motion technology, the system enables synchronized movement between the table and the arms. Surgeons operate the system using a console that features hand controls designed to mimic human motion with seven degrees of freedom, while software-controlled arms automatically adjust into programmed poses.
Timeline
July 2026: The Ottava system received FDA De Novo authorization.
The Tech Race
Johnson & Johnson is positioning Ottava to challenge the dominant cart-mounted surgical robotic architectures established by the da Vinci surgical system. This authorization serves as a key milestone in the company's long-term effort to capture share in the general surgery market.
Operating rooms may soon be reconfigured to accommodate the smaller footprint of the Ottava system compared to existing cart-mounted robotic platforms. Hospital procurement teams should expect to evaluate this system as an alternative for the 10 currently authorized general surgery procedures.
The takeaway
Johnson & Johnson is currently conducting an IDE study for inguinal hernia repair to expand the utility of the Ottava platform. Interested parties should track updates on the company's progress with its specialized Ethicon laparoscopic instrumentation suite designed for this system.
Further reading
For more on the latest developments in surgical automation, visit Robotics.
Source note: This article includes information reported by MDDI Online.
Live Poll
Do you believe new robotic surgical technology improves care and hospital efficiency in your community?
